title: Severe corneal changes following intravitreal injection of bevacizumab.
abstract: OBJECTIVE
  To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration.
  
  
  METHODS
  Retrospective noncomparative case series.
  
  
  METHODS
  The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab.
  
  
  RESULTS
  Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.
authors.affiliation: Department of Ophthalmology, Baskent University Hospital, Fevzi Cakmak cad. 10. Sokak, 06490 Bahcelievler, Ankara, Turkey. sezinakca@gmail.com
authors.forename: Sezin Akca
authors.initials: SA
authors.lastname: Bayar
authors.forename: Dilek D
authors.initials: DD
authors.lastname: Altinors
authors.forename: Cem
authors.initials: C
authors.lastname: Kucukerdonmez
authors.forename: Yonca A
authors.initials: YA
authors.lastname: Akova
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D015715:Corneal Edema / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D003886:Descemet Membrane / Q000276:immunology / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007634:Keratitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D000077266:Moxifloxacin; D011239:Prednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000068258:Bevacizumab; D003907:Dexamethasone; D011239:Prednisolone; D000077266:Moxifloxacin